Evidence map›Paper›PMID 38817906›Full record

ArticleFrontiers in oncology2024

Clinical characteristics, treatment patterns, and outcomes in adult patients with germline

Elias Obeid, Rohan C Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens, Lillian Shahied Arruda, Alexander Niyazov, Kristen Whitaker

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elias ObeidClinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States.
Rohan C ParikhHealth Economics, RTI Health Solutions, Research Triangle Park, NC, United States.
Elizabeth EsterbergHealth Economics, RTI Health Solutions, Research Triangle Park, NC, United States.
Bhakti ArondekarPfizer Inc., Collegeville, PA, United States.
Abigail HitchensHealth Economics, RTI Health Solutions, Research Triangle Park, NC, United States.
Lillian Shahied ArrudaPfizer Inc., Department of US Oncology Medical Affairs, New York, NY, United States.
Alexander NiyazovPfizer Inc., Department of HTA, Value and Evidence, New York, NY, United States.
Kristen WhitakerClinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To examine clinical characteristics, real-world treatment patterns, and health outcomes among patients with germline Methods: A retrospective analysis was conducted using medical records from patients with HER2-negative ABC with Results: When diagnosed with ABC, most patients were younger than 60 years (mean age = 57.3 years), were white (76.4%), and had a family history of Conclusion: Clinicians should consider the use of targeted agents such as PARP inhibitors in earlier lines of therapy for ABC given the growing evidence that PARP inhibitors may improve PFS compared with chemotherapy while potentially offering a more manageable toxicity profile and improved quality of life.

Indexed as

BRCA1/2 gene mutationshormone receptor-positive (HR+)human epidermal growth factor receptor 2 (HER2)-negativemetastatic breast cancerpoly (ADP-ribose) polymerase (PARP) inhibitorstriple-negative breast cancer (TNBC)

Identifiers

PMID38817906
PMCPMC11137205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.